Table 3:
Multivariable analysis of risk of venous and arterial thrombotic events among users of drospirenone-containing combined oral contraceptives relative to users of third-generation combined oral contraceptives
| Variable | Type of event; adjusted RR* (95% CI) | |
|---|---|---|
| DVT and PE | TIA and CVA | |
| Third-generation oral contraceptive† | Reference | Reference |
| Drospirenone-containing oral contraceptive‡ | 1.43 (1.15–1.78) | 0.97 (0.74–1.26) |
| Age, per year | 1.05 (1.04–1.06) | 1.08 (1.07–1.10) |
| Diabetes mellitus | 0.40 (0.13–1.24) | 1.42 (0.78–2.59) |
| Hyperlipidemia | 1.26 (0.94–1.69) | 1.20 (0.88–1.64) |
| Hypertension | 1.42 (0.90–2.26) | 2.16 (1.49–3.13 ) |
| Cancer | 3.37 (2.01–5.67 ) | 1.39 (0.65–2.94) |
| Smoking | 0.99 (0.80–1.23) | 1.19 (0.97–1.46) |
| Obesity | 1.72 (1.39–2.12) | 1.47 (1.19–1.83 ) |
| Duration of use, per month | 0.98 (0.97–0.98) | 0.97 (0.96–0.98) |
Note: CI = confidence interval, CVA = cerebrovascular accident, DVT = deep vein thrombosis, PE = pulmonary embolism, RR = rate ratio, TIA = transient ischemic attack.
For the overall comparison of drospirenone-containing oral contraceptives with third-generation oral contraceptives, RR was adjusted for all variables listed in the table. For each variable-specific comparison of drospirenone-containing oral contraceptives with third-generation oral contraceptives, RR was adjusted for all other variables listed.
No. of thrombotic events among users of third-generation combined oral contraceptives: venous = 384 (no. of woman-years of follow-up = 651 455), arterial = 382 (no. of woman-years of follow-up = 651 376).
No. of thrombotic events among users of drospirenone-containing combined oral contraceptives: venous = 99 (no. of woman-years of follow-up = 114 797), arterial = 66 (no. of woman-years of follow-up = 114 755).